Oncternal Therapeutics Stock Fundamentals
ONCT Stock | USD 8.20 0.15 1.86% |
Oncternal Therapeutics fundamentals help investors to digest information that contributes to Oncternal Therapeutics' financial success or failures. It also enables traders to predict the movement of Oncternal Stock. The fundamental analysis module provides a way to measure Oncternal Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncternal Therapeutics stock.
At this time, Oncternal Therapeutics' Interest Expense is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 2.3 M in 2024, whereas Operating Income is likely to drop (43.8 M) in 2024. Oncternal | Select Account or Indicator |
Oncternal Net Income Analysis
Oncternal Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
More About Net Income | All Equity Analysis
Oncternal Therapeutics Net Income |
|
Net Income | = | (Rev + Gain) | - | (Exp + Loss) |
Current Oncternal Therapeutics Net Income | (39.48 M) |
Most of Oncternal Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncternal Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition |
Oncternal Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Oncternal Therapeutics reported net income of (39.48 Million). This is 111.57% lower than that of the Biotechnology sector and 156.36% lower than that of the Health Care industry. The net income for all United States stocks is 106.91% higher than that of the company.
Oncternal Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oncternal Therapeutics's current stock value. Our valuation model uses many indicators to compare Oncternal Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncternal Therapeutics competition to find correlations between indicators driving Oncternal Therapeutics's intrinsic value. More Info.Oncternal Therapeutics is regarded third in working capital category among related companies. It is rated below average in earnings per share category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Oncternal Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oncternal Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oncternal Therapeutics' earnings, one of the primary drivers of an investment's value.Oncternal Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncternal Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncternal Therapeutics could also be used in its relative valuation, which is a method of valuing Oncternal Therapeutics by comparing valuation metrics of similar companies.Oncternal Therapeutics is currently under evaluation in beta category among related companies.
Oncternal Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Oncternal Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Oncternal Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oncternal Therapeutics' value.Shares | Two Sigma Advisers, Llc | 2023-12-31 | 83.6 K | Two Sigma Investments Llc | 2023-12-31 | 74.7 K | Acadian Asset Management Llc | 2023-12-31 | 72.8 K | Axxcess Wealth Management, Llc | 2023-12-31 | 70.4 K | Two Sigma Securities, Llc | 58.8 K | Regents Of The University Of California | 2023-12-31 | 53.6 K | Balboa Wealth Partners | 2023-12-31 | 47.5 K | Creative Planning Inc | 2023-12-31 | 39.3 K | Charles Schwab Investment Management Inc | 2023-12-31 | 32.2 K | Vanguard Group Inc | 2023-12-31 | 2.9 M | Millennium Management Llc | 2023-12-31 | 2.1 M |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oncternal Therapeutics will likely underperform.
Oncternal Fundamentals
Return On Equity | -0.87 | ||||
Return On Asset | -0.49 | ||||
Operating Margin | (32.44) % | ||||
Current Valuation | (10.1 M) | ||||
Shares Outstanding | 2.96 M | ||||
Shares Owned By Insiders | 8.41 % | ||||
Shares Owned By Institutions | 16.14 % | ||||
Number Of Shares Shorted | 15 K | ||||
Price To Earning | (37.77) X | ||||
Price To Book | 0.79 X | ||||
Price To Sales | 30.37 X | ||||
Revenue | 785 K | ||||
Gross Profit | (31.49 M) | ||||
EBITDA | (41.71 M) | ||||
Net Income | (39.48 M) | ||||
Cash And Equivalents | 78.9 M | ||||
Cash Per Share | 1.48 X | ||||
Total Debt | 318 K | ||||
Debt To Equity | 0 % | ||||
Current Ratio | 10.78 X | ||||
Book Value Per Share | 10.19 X | ||||
Cash Flow From Operations | (32.16 M) | ||||
Short Ratio | 1.87 X | ||||
Earnings Per Share | (13.43) X | ||||
Target Price | 31.33 | ||||
Number Of Employees | 27 | ||||
Beta | 1.37 | ||||
Market Capitalization | 23.84 M | ||||
Total Asset | 36.73 M | ||||
Retained Earnings | (197.78 M) | ||||
Working Capital | 30.86 M | ||||
Current Asset | 27.27 M | ||||
Current Liabilities | 6.3 M | ||||
Z Score | 34.72 | ||||
Net Asset | 36.73 M |
About Oncternal Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncternal Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncternal Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncternal Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
Current Deferred Revenue | 1.5 M | 1.4 M | |
Total Revenue | 785 K | 745.8 K | |
Cost Of Revenue | 205.8 K | 195.6 K | |
Ebit Per Revenue | (53.14) | (50.48) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Oncternal Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Oncternal Therapeutics' short interest history, or implied volatility extrapolated from Oncternal Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Oncternal Therapeutics Piotroski F Score and Oncternal Therapeutics Altman Z Score analysis. For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.Note that the Oncternal Therapeutics information on this page should be used as a complementary analysis to other Oncternal Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Oncternal Stock analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Oncternal Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.43) | Revenue Per Share 0.267 | Quarterly Revenue Growth 0.737 | Return On Assets (0.49) | Return On Equity (0.87) |
The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.